Acamprosate

Summary

Acamprosate (CHEMBL1201293) is an approved small-molecule neurotransmitter agent (ATC N07BB03); indicated across 13 conditions including alcohol abuse and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N07BB03
• Indications: 13 conditions
• Clinical trials: 42
• Chemistry: 181.21 Da · C5H11NO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201293
Name	Acamprosate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	71158
ChEBI	CHEBI:51041
ATC	N07BB03
Molecular formula	C5H11NO4S
Molecular weight	181.21
InChIKey	AFCGFAGUEYAMAO-UHFFFAOYSA-N

SMILES: CC(=O)NCCCS(=O)(=O)O

IUPAC name: 3-acetamidopropane-1-sulfonic acid

ChEBI definition: An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.

Pharmacological roles (ChEBI): neurotransmitter agent.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Acamprosate, Acamprosato, Aotal, acamprosate, SID50112716, ACAMPROSATE, ACAMPROSATE CALCIUM

Parent form; salt/anhydrous children: CHEMBL2068724

Patent coverage: 1,400 distinct patent families (4,891 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
alcohol abuse	4	MONDO:0002046	MONDO:0007079

10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
cocaine dependence	2	MONDO:0005186	EFO:0002610
autism spectrum disorder	2	MONDO:0005258	EFO:0003756
eating disorder	2	MONDO:0005451	EFO:0005203
fragile X syndrome	2	MONDO:0010383	MONDO:0010383
essential tremor	2	MONDO:0003233	EFO:0003108
autism	1	MONDO:0005260	EFO:0003758
methamphetamine dependence	1	MONDO:0005419	EFO:0004701

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE4	14
PHASE2	11
Not specified	5
PHASE3	4
PHASE1	4
PHASE1/PHASE2	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06269627	PHASE4	RECRUITING	Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
NCT00120601	PHASE4	UNKNOWN	Trial for the Treatment of Alcohol Dependence
NCT00159107	PHASE4	COMPLETED	Integrative Therapy in Alcoholism
NCT00249379	PHASE4	TERMINATED	Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees
NCT00330174	PHASE4	COMPLETED	Acamprosate in Alcoholics With Comorbid Anxiety or Depression
NCT00381043	PHASE4	COMPLETED	Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic
NCT00435435	PHASE4	COMPLETED	Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence
NCT00452543	PHASE4	COMPLETED	Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
NCT00466661	PHASE4	COMPLETED	Acamprosate vs. Placebo in Bipolar Alcoholics
NCT00571103	PHASE4	COMPLETED	Acamprosate in the Treatment of Pathological Gambling
NCT00655967	PHASE4	WITHDRAWN	Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)
NCT00688324	PHASE4	COMPLETED	Biomarker Study of Acamprosate in Schizophrenia
NCT00855699	PHASE4	COMPLETED	Alcohol Detoxification in Primary Care Treatment (ADEPT)
NCT03818191	PHASE4	COMPLETED	Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
NCT00006206	PHASE3	COMPLETED	COMBINE (Acamprosate/Naltrexone)
NCT00463346	PHASE3	COMPLETED	Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
NCT00511940	PHASE2/PHASE3	COMPLETED	Acamprosate in the Treatment of Binge-Eating Disorder
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT03634917	PHASE3	COMPLETED	Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence
NCT07060638	PHASE2	RECRUITING	Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
NCT00004552	PHASE2	COMPLETED	Acamprosate Treatment: Mechanisms of Action
NCT00106106	PHASE2	COMPLETED	Acamprosate to Reduce Symptoms of Alcohol Withdrawal
NCT00330486	PHASE1/PHASE2	COMPLETED	Open Label Trial of Acamprosate in Bipolar Alcoholics
NCT00360594	PHASE2	COMPLETED	Acamprosate Initiated During Alcohol Detoxification
NCT00385268	PHASE2	COMPLETED	Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence
NCT00571922	PHASE1/PHASE2	COMPLETED	A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
NCT00605904	PHASE2	COMPLETED	Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
NCT00656630	PHASE2	COMPLETED	Medication Development in Alcoholism: Acamprosate Versus Naltrexone
NCT01300923	PHASE2	COMPLETED	Acamprosate in Youth With Fragile X Syndrome
NCT04498897	PHASE2	UNKNOWN	Vortioxetine for Treatment of Depressive Mood and Alcohol Use
NCT06312800	PHASE2	WITHDRAWN	Acamprosate and Methazolamide for Essential Tremor
NCT06471686	PHASE2	COMPLETED	Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations
NCT07204977	PHASE1	ACTIVE_NOT_RECRUITING	Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
NCT00596531	PHASE1	COMPLETED	Clinical Trial of Acamprosate for Tinnitus
NCT01813318	PHASE1	COMPLETED	Study of Acamprosate in Autism
NCT01911455	PHASE1	COMPLETED	Study of Acamprosate in Fragile x Syndrome
NCT02998151	EARLY_PHASE1	COMPLETED	Neurophysiological and Acute Pharmacological Studies in FXS Patients
NCT00425711	Not specified	TERMINATED	Study of Acamprosate in Driving Under the Influence (DUI) Court Participants
NCT00591565	Not specified	COMPLETED	An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants
NCT00640952	Not specified	WITHDRAWN	Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson’s Disease
NCT00662571	Not specified	COMPLETED	Acamprosate: Genes Associated With Response
NCT04287790	Not specified	TERMINATED	Promoting Medications for Alcohol Use Disorder on the General Medicine Service

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).